Regulation of dietary supplements in the United States of America

Clinical Research and Regulatory Affairs

Volumn 20, Issue 3, 2003, Pages 313-325

  Dvorkin, Lana ^a   Gardiner, Paula M ^b  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIET SUPPLEMENTATION; DRUG INDUSTRY; DRUG INFORMATION; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG SAFETY; HEALTH CARE PERSONNEL; HERBAL MEDICINE; MEDICAL EDUCATION; PATIENT EDUCATION; REVIEW; UNITED STATES;

EID: 0042472934     PISSN: 10601333     EISSN: None     Source Type: Journal    
DOI: 10.1081/CRP-120023844     Document Type: Review

References (27)

1. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M. et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 1998; 280(18):1569-1575.
2. Zeisel S. Regulation of "Nutraceuticals." Science 1999; 285(17):1853-1855.
3. Marcus DM, Grollman AP. Botanical Medicines - The Need for New Regulations. NEJM 2002; 347(25):2073-2076.
4. Overview and History of FDA and the Center for Food Safety and Applied Nutrition. Available at http://www.cfsan.fda.gov/~lrd/fdahist.html. Accessed January 10, 2003.
5. FDA Consumer: The Story of the Laws Behind the Labels. Part 1-1906 - Food and Drug Act. 1981 Available at http://www.cfsan.fda.gov/~lrd/history1. html Accessed December 20, 2003.
6. FDA Consumer: The Story of the Laws Behind the Labels. Part II-1938 - The Federal Food, Drug, and Cosmetic Act. 1981. Available at htm://www.efsan.fda.gov/~lrd/histor1a.html. Accessed December 20, 2003.
7. FDA Consumer: The Story of the Laws Behind the Labels. Part III-1962 Drug Amendments. 1981. Available at http:/www.cfsan.fda.gov/~lrd/ histor1b.html. Accessed December 20, 2003.
8. Robbers JE, Tyler VE. Tyler's Herbs of Choice: The Therapeutic Use of Phytomedicinals. New York: Haworth Herbal Press, 1999; 17-31.
9. Young A, Bass IS. The dietary supplement health and education act. Food and Drug Law Journal, 1995, 50:285-292.
10. Henney JE. Statement by Commissioner Food and Drug Administration, Department of Health and Human Services before the Committee on Government Reform, U.S. House of Representatives. March 25, 1999. Available at http://www.fda.gov/ola/dietary.html. Accessed on December 20, 2002.
11. U.S. FDA. Anatomy of the New Requirements for Dietary Supplement Labels. Available at http://www.cfsan.fda.gov/~acrobat/fdsuppla.pdf. Accessed March 13, 2003.
12. Dietary Supplements: An Advertising Guide for Industry. Available at http:// www.ftc.gov/bcp/conline/pubs/buspubs/dietsupp.htm. Accessed December 20, 2002.
13. Leva E. Demanding Higher Quality Dietary Supplements. Herb and Dietary Supplement Report. Part 3. February 2000; 7.
14. Blumenthal M. Hall Herbalgram 2001; 52:24-25.
15. Leva E. Demanding Higher Quality Dietary Supplements. Herb and Dietary Supplement Report. Part 2. January 2000; 7.
16. Perlman BB. Interaction between lithium salts and ispaghula husk. Lancet Feb. 17, 1990; 335(8686):416.
17. Fugh-Berman A. Herb-Drug interactions. Lancet 2000; 355:134-138.
18. Bouraoui A, Toumi A, Ben Mustapha H, Brazier JL. Effects of capsicum fruit on theophylline absorption and bioavailability. Drug-Nutrient Interactions 1988; 5(4):345-350.
19. Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G. Acute heart transplant rejection due to Saint John's wort. Lancet Feb. 12, 2000; 355(9203):548-549.
20. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St John's wort.[erratum appears in Lancet Apr. 14, 2001; 357(9263):1210]; Lancet 12 Feb, 2000; 355(9203):547-548.
21. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St John's wort.[erratum appears in Lancet Apr. 14, 2001; 357(9263):1210]; Lancet 12 Feb, 2000; 355(9203):547-548.
22. Johne A, Brockmoller J, Bauer S, Maurer A, Langheinrich M, Roots I. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clinical Pharmacology and Therapeutics October 1999; 66(4):338-345.
23. Yue QY, Bergquist C, Gerden B. Safety of St John's wort (Hypericum perforatum). Lancet Feb. 12, 2000; 355(9203):576-577.
24. FDA Safety Information and Adverse Events Reporting Program. Available at http://www.fdao.gv/medwatch/report/hcp.htm. Accessed January 15, 2003.
25. US Food and Drug Administration. Center for Food Safety and Applied Nutrition. Office of Scientific Analysis and Support. Letter to Stakeholders: Announcing CAERS - the CFSAN Adverse Event Reporting System. August 29, 2002 Available at http://www.cfsan.fda.gov/~dms/caersltr.html. Accessed January 15, 2003.
26. Miller L, Hume A, Mehra Harris I, Jackson E, Kanmaz T, Cauffield J, et al. ACCP white paper on herbal products. Pharmacotherapy 2000; 20(7):877-891.
27. U.S. Food and Drug Administration. FDA News. HHS Acts to Reduce Potential Risks of Dietary Supplements Containing Ephedra. Available at http://www.fda.gov/bbs/topics/NEWS/2003NEW00875.html. Accessed March 2003.